-
Isolated massive pleural effusion as a manifestation of chronic graft versus host disease successfully treated with corticosteroid Ann. Hematol. (IF 3.5) Pub Date : 2024-04-01
Abstract Isolated pleural effusion is a rare manifestation of chronic graft versus host disease (cGVHD) after hematopoietic stem cell transplantation (HSCT). We herein report a 58-year-old woman presenting with massive pleural effusion approximately 1 year after allogeneic HSCT, who was successfully treated with corticosteroid. She had discontinued tacrolimus approximately 1 month before she presented
-
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation Ann. Hematol. (IF 3.5) Pub Date : 2024-04-01
Abstract Measurable residual disease (MRD) monitoring independently predicts long-term outcomes in patients with acute myeloid leukemia (AML). Of the various modalities available, multiparameter flow cytometry–based MRD analysis is widely used and relevant for patients without molecular targets. In the transplant (HCT) setting, the presence of MRD pre-HCT is associated with adverse outcomes. MRD-negative
-
The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms Ann. Hematol. (IF 3.5) Pub Date : 2024-03-13 Hrvoje Holik, Marko Lucijanić, Ivan Krečak
-
Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation Ann. Hematol. (IF 3.5) Pub Date : 2024-03-13 Te-Lin Hsu, Chun-Kuang Tsai, Chun-Yu Liu, Chiu-Mei Yeh, Fen-Lan Lin, Liang-Tsai Hsiao, Yao-Chung Liu, Sheng-Hsuan Chien, Hao-Yuan Wang, Po-Shen Ko, Ting-An Lin, Wen-Chun Chen, Po-Min Chen, Jin-Hwang Liu, Jyh-Pyng Gau, Chia-Jen Liu
-
Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection Ann. Hematol. (IF 3.5) Pub Date : 2024-03-12 Yuanfang Li, Sanjing Li, Nadan Lu, Weilin Wang, Dao Wang
-
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices Ann. Hematol. (IF 3.5) Pub Date : 2024-03-12
Abstract Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized centers whereas primary care for patients (pts) with CML is mainly provided by local oncology practices. The aim of this study was to assess treatment practices in pts with CML in the setting of private oncology practices in Germany. We collected data of 819 pts with a confirmed diagnosis (dx) of CML in
-
Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study Ann. Hematol. (IF 3.5) Pub Date : 2024-03-09
Abstract Histological transformation into an aggressive B-cell lymphoma indicates a poor survival outcome for patients with indolent marginal zone lymphoma (MZL), which has been less studied. Large-scale data with long-term follow-up to investigate MZL transformation is limited. Here, by reporting a US-Nationwide cohort of 30,619 MZL patients diagnosed between 2000 and 2019, we found that transformation
-
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009–2020 Ann. Hematol. (IF 3.5) Pub Date : 2024-03-09
Abstract Multiple myeloma (MM) is an incurable hematological cancer requiring multiple lines of anti-myeloma regimens to promote disease remission and increase patient survival. The study assessed the incidence and reasons for discontinuation of first-line therapy in outpatients who started MM therapy in Belo Horizonte, Brazil from 2009 to 2020. A historical cohort study in which patients were followed
-
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group Ann. Hematol. (IF 3.5) Pub Date : 2024-03-09 Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling
-
Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population Ann. Hematol. (IF 3.5) Pub Date : 2024-03-08 Emily L. Gill, Christian M. Gill, Colleen McEvoy
-
A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors Ann. Hematol. (IF 3.5) Pub Date : 2024-03-08 Wenjie Li, Yiming Fu, Wei Wang
-
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan Ann. Hematol. (IF 3.5) Pub Date : 2024-03-08 Mendy ter Avest, Saskia M.C Langemeijer, Nicole M.A. Blijlevens, Nicole C.A.J. van de Kar, Rob ter Heine
-
Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-03-07 Jiawang Ou, Shiyu Deng, Chenhao Ding, Zihong Cai, Junjie Chen, Zicong Huang, Xiuli Xu, Jia Li, Zhengwei Wu, Bingqing Tang, Ting Zhang, Zhixiang Wang, Ya Zhou, Li Xuan, Qifa Liu, Hongsheng Zhou
-
Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia Ann. Hematol. (IF 3.5) Pub Date : 2024-03-06
Abstract Waldenström macroglobulinemia (WM) is a type of B-cell lymphoma that produces IgM. Our study aimed to investigate the role of CXCL13, a chemokine essential for B lymphocytes, in the evaluation of treatment response and prognosis in WM. We collected serum samples and clinical data from 72 WM patients, with 69 patients receiving systemic therapy and 3 patients opting not to receive treatment
-
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma Ann. Hematol. (IF 3.5) Pub Date : 2024-03-06 Hongpeng Duan, Qiuhui Jiang, Long Liu, Manman Deng, Qian Lai, Yuelong Jiang, Zhifeng Li, Bing Xu, Zhijuan Lin
-
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study Ann. Hematol. (IF 3.5) Pub Date : 2024-03-06
Abstract We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractory CLL or to previously untreated CLL patients with deletion
-
Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification Ann. Hematol. (IF 3.5) Pub Date : 2024-03-06 Synne D. Rørvik, Synne Torkildsen, Øystein Bruserud, Tor Henrik Anderson Tvedt
Two different systems exist for subclassification of acute myeloid leukemia (AML); the World Health Organization (WHO) Classification and the International Consensus Classification (ICC) of myeloid malignancies. The two systems differ in their classification of AML defined by recurrent chromosomal abnormalities. One difference is that the ICC classification defines an AML subset that includes 12 different
-
Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome–positive acute lymphoblastic leukaemia Ann. Hematol. (IF 3.5) Pub Date : 2024-03-05
Abstract The application of tyrosine kinase inhibitors (TKIs) and novel immunotherapies has improved outcomes in patients with Ph + acute lymphoblastic leukaemia (ALL), and the issue of whether there is still a need for stem cell transplantation has become controversial. We performed a retrospective study to explore whether stem cell transplantation still held a place in patients with Ph + ALL if only
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann. Hematol. (IF 3.5) Pub Date : 2024-03-04 Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Döhner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Valentin García-Gutierrez, Florian H.
-
Analysis of four hereditary protein C deficiencies associated with vascular thromboembolism Ann. Hematol. (IF 3.5) Pub Date : 2024-03-04
Abstract Objective: To analyze the clinical features and gene mutations in four families with hereditary protein C (PC) deficiency and explore their association with vascular thromboembolism. Methods: The clinical data of four patients with PC deficiency were retrospectively analyzed. Venous blood samples were collected from the four affected patients and their family members, and relevant coagulation
-
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies Ann. Hematol. (IF 3.5) Pub Date : 2024-03-02 Patrick Reimann, Verena Petzer, Axel Mündlein, Bernd Hartmann, Luciano Severgnini, Alex Winkler, Theresia Lang, Minh Huynh, Klaus Gasser, Julia Rüger, Michele Atzl, Sylvia Mink, Peter Fraunberger, Stefan Schmidt, Normann Steiner, Andrea Griesmacher, Eberhard Gunsilius, David Nachbaur, Wolfgang Willenbacher, Dominik Wolf, Thomas Winder, Magdalena Anna Benda
-
Outcomes of haploidentical peripheral blood stem cell transplantation following myeloablative conditioning using two types of rabbit ATG: a propensity score-matched analysis Ann. Hematol. (IF 3.5) Pub Date : 2024-03-02 Zhuoyue Shi, Fei Gao, Dang Ding, Hengwei Wu, Jimin Shi, Yi Luo, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
-
Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature Ann. Hematol. (IF 3.5) Pub Date : 2024-03-02 Santiago Mercadal, Alberto Mussetti, Catherine J. Lee, Carolina Arevalo, Silvina M. Odstrcil, Esteban Peña, Anna Sureda, Daniel R. Couriel
-
Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-02-27 Yi Chen, Jing Zheng, Yimei Weng, Zhengjun Wu, Xiaofeng Luo, Yanyan Qiu, Yanjuan Lin, Jianda Hu, Yong Wu
-
Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching Ann. Hematol. (IF 3.5) Pub Date : 2024-02-23 Sheng-Hsuan Chien, Hsin-Yi Huang, Ying-Ju Chen, Yu-Chen Tsai, Shu-Hua Lu, Li-Hsuan Lee, Hsueng-Mei Liu, Wen-Chun Chen, Yao-Chung Liu, Ting-An Lin, Chun-Yu Liu
-
Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke Ann. Hematol. (IF 3.5) Pub Date : 2024-02-22 Júlia Nicoliello Pereira de Castro, Sueli Matilde da Silva Costa, Ana Carolina Lima Camargo, Mirta Tomie Ito, Bruno Batista de Souza, Victor de Haidar e Bertozzo, Thiago Adalton Rosa Rodrigues, Carolina Lanaro, Dulcinéia Martins de Albuquerque, Roberta Casagrande Saez, Sara Teresinha Olalla Saad, Margareth Castro Ozelo, Fernando Cendes, Fernando Ferreira Costa, Mônica Barbosa de Melo
-
Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study Ann. Hematol. (IF 3.5) Pub Date : 2024-02-21 Shuang Fan, Xiaodong Mo, Xiaohui Zhang, LanPing Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuanyuan Zhang, Yifei Cheng, Yuqian Sun, Yuhong Chen, Yao Chen, Wei Han, Jingzhi Wang, Fengrong Wang, Zhengli Xu, Xiaojun Huang
-
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration Ann. Hematol. (IF 3.5) Pub Date : 2024-02-20 Takayuki Goto, Nobuhiko Nakamura, Tomomi Suzaki, Ryoma Shimazu, Yuto Kaneda, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Nobuhiro Kanemura, Masahito Shimizu
-
Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers Ann. Hematol. (IF 3.5) Pub Date : 2024-02-13 Rasoul Ebrahimi, Fatemeh Nasri, Tahereh Kalantari
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as 2019-nCoV. Numerous cellular and biochemical issues arise after COVID-19 infection. The severe inflammation that is caused by a number of cytokines appears to be one of the key hallmarks of COVID-19. Additionally, people with severe COVID-19 have coagulopathy and fulminant
-
Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis Ann. Hematol. (IF 3.5) Pub Date : 2024-02-10 Kailun David Zhang, Edgar Jost, Jens Panse, Reinhild Herwartz, Katharina Lindemann-Docter, Danny Jonigk, Kim Kricheldorf, Anja Köchel, Nicolas Sauerbrunn, Tim H. Brümmendorf, Steffen Koschmieder, Susanne Isfort
-
Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study Ann. Hematol. (IF 3.5) Pub Date : 2024-02-08 Lei Zhao, Jinjun Yang, Mengran Chen, Xinrong Xiang, Hongbing Ma, Ting Niu, Yuping Gong, Xinchuan Chen, Jiazhuo Liu, Yu Wu
-
The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies Ann. Hematol. (IF 3.5) Pub Date : 2024-02-08 Qi Zhang, Xiaojian Zhu, Yi Xiao
-
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape Ann. Hematol. (IF 3.5) Pub Date : 2024-02-07 Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
-
Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance Ann. Hematol. (IF 3.5) Pub Date : 2024-02-07 Sha Cui, Yinnan Guo, Jianting Li, Wenjin Bian, Wenqi Wu, Wenjia Zhang, Qian Zheng, Haonan Guan, Jun Wang, Jinliang Niu
-
Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation Ann. Hematol. (IF 3.5) Pub Date : 2024-02-06 Yuanyuan Ren, Fang Liu, Xia Chen, Xiaoyan Zhang, Beibei Zhao, Yang Wan, Yang Lan, Xiaolan Li, Wenyu Yang, Xiaofan Zhu, Ye Guo
-
Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study Ann. Hematol. (IF 3.5) Pub Date : 2024-02-03 Wenqi Li, Yu Chang, Xiyang Liu, Ziqi Chen, Jinmiao Sun, Zurui Geng, Mingzhi Zhang, Lei Zhang
-
A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia Ann. Hematol. (IF 3.5) Pub Date : 2024-02-03 Liyan Yang, Haiyue Niu, Tian Zhang, Qiuying Cao, Mengyuan Liu, Yumei Liu, Li Yan, Weiwei Qi, Ting Wang, Chunyan Liu, Lijuan Li, Limin Xing, Huaquan Wang, Zonghong Shao, Rong Fu
-
Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-02-03 Pascal Schlosser, Annett Schiwitza, Jonas Klaus, Stefanie Hieke-Schulz, Katarzyna Szarc vel Szic, Justus Duyster, Martin Trepel, Katja Zirlik, Martin Schumacher, Rainer Claus
-
Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-01-31 Yue Chen, Mengge Pan, Lanxin Chen, Miaoxin Peng, Zhenyu Liu, Yiran Fang, Ying Du, Yonggong Yang, Peipei Xu
-
Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut Ann. Hematol. (IF 3.5) Pub Date : 2024-01-27 Blanca Vegas Villalmanzo, Rodrigo Cantera Estefanía, Sara Muñoz Madrid, Mariana Cerrato Salas, Irene Arnaiz Martín, Marta Molina Pérez, Beatriz Sagrista López, Yolanda Ruiz Ramírez, Javier Cucharero Martín, Pablo Estival Monteliú, Paloma Ropero Gradilla, Sara Ferrer Benito, María Paz Martín Hernández, Fernando Ataulfo González Fernández, Miguel Gómez Álvarez, Ana Villegas Martínez, Celina Benavente
It has been proposed that the onset of Acquired Thrombotic Thrombocytopenic Purpura (iTTP) is more severe than subsequent relapses; however, existing studies have limitations. We conducted a retrospective observational study to compare analytical and clinical severity of onset and relapse aTTP cases between 2012 and 2023. A total of 370 episodes of aTTP were analyzed, comprising 272 at initial diagnosis
-
Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology Ann. Hematol. (IF 3.5) Pub Date : 2024-01-24 Marta Garrote, Mónica López-Guerra, Juan Carlos García-Pagán, Eduardo Arellano-Rodrigo, Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, Beatriz Bellosillo, Meritxell Nomdedeu, Virginia Hernández-Gea, Ana Triguero, Francesca Guijarro, José Álamo, Anna Baiges, Fanny Turon, Dolors Colomer, Francisco Cervantes, Alberto Alvarez-Larrán
-
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab Ann. Hematol. (IF 3.5) Pub Date : 2024-01-18 Min Qing, Tianyuan Zhou, Tatiana Perova, Yann Abraham, Cheryl Sweeney, Maria Krevvata, Xiaokang Zhang, Ming Qi, Grace Gao, Tae Min Kim, Ming Yao, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yok Lam Kwong, Dok Hyun Yoon, Jin Seok Kim, Won Seog Kim, Longen Zhou, Ricardo Attar, Raluca I. Verona
-
Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis Ann. Hematol. (IF 3.5) Pub Date : 2024-01-18
Abstract Chronic Lymphocytic Leukemia (CLL) is well-known for increasing susceptibility to infections. Factors such as immune dysregulation, IGHV status, hypogammaglobulinemia, and patient comorbidity and treatment, contribute to higher infection rates and mortality. However, the impact of hypogammaglobulinemia on infection rates is controversial. We aimed to identify clinical and biological parameters
-
Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms Ann. Hematol. (IF 3.5) Pub Date : 2024-01-17 Velizar Shivarov, Gergana Tsvetkova, Bisera Atanasova, Mariana P. Genova, Irena Ivanova, Evgueniy Hadjiev, Milena Ivanova
-
Negative effect of paraskeletal plasmacytoma on survival of patients with transplant-ineligible newly diagnosed multiple myeloma Ann. Hematol. (IF 3.5) Pub Date : 2024-01-16 Junzhe Wang, Xiaoning Song, Xian Zhang, Han Liu, Meirong Zang, Dianwen Qi, Jinqiao Zhang, Lixia Sun
-
The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping Ann. Hematol. (IF 3.5) Pub Date : 2024-01-16
Abstract Cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a challenging problem, and the impact on the risk of overall mortality (OM) and non-relapse mortality (NRM) in patients following allo-HSCT is still controversial. Utilizing the evidence mapping method, we aimed to assess the effect of CMV infection on outcomes of patients post-transplantation
-
Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century Ann. Hematol. (IF 3.5) Pub Date : 2024-01-16 Li-Ye Bei, Chun-Yu Shang, Jia-Zhu Wu, Hao-Rui Shen, Hua Yin, Jin-Hua Liang, Xin-Yu Zhang, Li Wang, Jian-Yong Li, Yue Li, Wei Xu
-
VEXAS syndrome: complete molecular remission after hypomethylating therapy Ann. Hematol. (IF 3.5) Pub Date : 2024-01-12 Katja Sockel, Katharina Götze, Christina Ganster, Marius Bill, Julia-Annabell Georgi, Ekaterina Balaian, Martin Aringer, Karolin Trautmann-Grill, Maria Uhlig, Martin Bornhäuser, Detlef Haase, Christian Thiede
-
Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy Ann. Hematol. (IF 3.5) Pub Date : 2024-01-12 Yifan Zhao, Xiaomei Zhang, Meng Zhang, Ruiting Guo, Yi Zhang, Yedi Pu, Haibo Zhu, Pengjiang Liu, Yu Zhang, Xiaoyuan He, Cuicui Lyu, Hairong Lyu, Xia Xiao, Mingfeng Zhao
-
1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study Ann. Hematol. (IF 3.5) Pub Date : 2024-01-11
Abstract 1q21+ is a common cytogenetic abnormality in multiple myeloma (MM) and is considered an independent predictor of poor prognosis; however, its impact on extramedullary disease (EMD) remains unknown. Our study reviewed the clinical relevance and prognostic value of 1q21+ status in 92 patients with NDMM and EMD. 1q21+ was detected in 23.9% (22/92) of patients. Patients with 1q21+ presented with
-
A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio Ann. Hematol. (IF 3.5) Pub Date : 2024-01-10 Cuicui Feng, Zhengjie Hua, Lingbo He, Shuyan Yao, Heshan Zou, Yingxin Zhu, Zhao Wang, Yini Wang
-
Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center Ann. Hematol. (IF 3.5) Pub Date : 2024-01-09 Alice Kennedy, Shyam Patel, Muthalagu Ramanathan, Jonathan Gerber, Jan Cerny
-
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript Ann. Hematol. (IF 3.5) Pub Date : 2024-01-09 Julien Dereme, Sophie Voruz, Françoise Solly, Jacqueline Schoumans, Sabine Blum
-
Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK/T-cell lymphoma Ann. Hematol. (IF 3.5) Pub Date : 2024-01-09 Fei Qi, Yuce Wei, Meng Wu, Yan Sun, Yan Xie, Ningjing Lin, Weiping Liu, Weihu Wang, Yuqin Song, Jun Zhu
-
Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations Ann. Hematol. (IF 3.5) Pub Date : 2024-01-09 Evgenii Shumilov, Paolo Mazzeo, Susanne Ghandili, Axel Künstner, Sören Weidemann, Yara Banz, Philipp Ströbel, Matthias Pollak, Lina Kolloch, Helmut Beltraminelli, Andrea Kerkhoff, Jan-Henrik Mikesch, Christoph Schliemann, Detlef Haase, Gerald Wulf, Myriam Legros, Georg Lenz, Laurence Feldmeyer, Thomas Pabst, Hanno Witte, Niklas Gebauer, Ulrike Bacher
-
How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials Ann. Hematol. (IF 3.5) Pub Date : 2024-01-08 Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Zoi Bezirgianidou, Menelaos Papoutselis, Christina Misidou, Christoforos Roumpakis, Athina Spanoudaki, Konstantinos Liapis, Emmanouil Spanoudakis
-
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim Ann. Hematol. (IF 3.5) Pub Date : 2024-01-08 Francesco Marchesi, Irene Terrenato, Elena Papa, Martina Tomassi, Paolo Falcucci, Svitlana Gumenyuk, Francesca Palombi, Francesco Pisani, Daniela Renzi, Atelda Romano, Antonio Spadea, Giulia Regazzo, Maria Giulia Rizzo, Mafalda De Rienzo, Claudio Ripellino, Simona Sgromo, Caterina Viggiani, Eleonora Ponte, Ramy Kayal, Iole Cordone, Maria Laura Foddai, Andrea Mengarelli
Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among lymphoma and myeloma patients undergoing ASCT, comparing these data with historical controls receiving other G-CSFs. Furthermore, an economic evaluation has been included to estimate the savings by using bioPEG. This is
-
A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-01-06
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive myeloid malignancy which characteristically expresses an atypical phenotype including CD123+, CD56+, and CD4+. We are aimed to investigate the clinical and prognostic characteristics of AML patients exhibiting BPDCN-like immunophenotype and provide additional insights for risk stratification of AML. A total of 241
-
Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia Ann. Hematol. (IF 3.5) Pub Date : 2024-01-05 Luiza Lapolla Perruso, Elvira Velloso, Vanderson Rocha, Eduardo Magalhaes Rego, Wellington Fernandes Silva
-
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study) Ann. Hematol. (IF 3.5) Pub Date : 2024-01-04 Carlos Vallejo, Ana Rosell, Blanca Xicoy, Carmen García, Carmen Albo, Marta Polo, Isidro Jarque, Brígida Esteban, M. Lorena Codesido